Key result
Left ventricular hypertrophy and previous antihypertensive treatment were confirmed as significant risk factors for mortality among 24,390 hypertensive patients (1,726 deaths over 5 years).
Cohort (n=24,390)
Yes
Left ventricular hypertrophy and previous antihypertensive treatment are significant risk factors for cardiovascular mortality in hypertensive patients, whereas the prognostic value of diastolic blood pressure is age-dependent.
Answers are grounded in this paper and cite their sources.
LVH and prior antihypertensive treatment warrant closer risk stratification in hypertensives; confirms their independent mortality association in large-scale data.
BACKGROUND: Predicting individual risk is needed to target preventive interventions toward people with the highest probability of benefit over a given time period. We assessed which prognostic factors should be used in predicting risk for hypertensive patients and in searching for treatment modifiers. METHODS AND RESULTS: Data from 24 390 hypertensive participants who constituted the control groups from 8 controlled trials (1726 deaths over 5 years) were analyzed in multivariate survival models. Outcomes were coronary heart disease death, stroke death, and cardiovascular death. We explored systematically the heterogeneity of results between trials. Left ventricular hypertrophy was electrocardiographically confirmed to be a powerful risk factor and should be included in risk scoring. Height, glomerular filtration rate, and serum uric acid deserve further exploration. Body mass index and heart rate were not confirmed as independent cardiovascular risk factors in this population. The association between male sex and coronary heart disease death was significantly stronger in British cohorts. The lack of prognostic value of diastolic blood pressure was explained by an interaction with age, with a positive association before 65 years and a negative association thereafter. Previous antihypertensive treatment was a significant risk factor. CONCLUSIONS: Clinical trials provide valuable information for risk prediction. Carefully exploring the heterogeneity among trials is a way to assess the generalizability of findings. This approach, if systematically performed, should increase the ability to identify risk modifiers and to predict individual therapeutic benefit.
No takes yet. Share an insight, caveat, or question.
Gueyffier et al. (1999) conducted a cohort in Hypertension (n=24,390). Left ventricular hypertrophy and previous antihypertensive treatment were confirmed as significant risk factors for mortality among 24,390 hypertensive patients (1,726 deaths over 5 years).
Synapse has enriched 10 related papers. Consider them for comparative context: